Last updated on July 2019

An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington's Disease Patients Who Participated in Prior Roche and Genentech Sponsored Studies


Brief description of study

This study will evaluate the long-term safety and tolerability of RO7234292 (RG6042) in participants who have completed other F. Hoffmann-La Roche, Ltd.-sponsored and/or Genentech-sponsored studies in the Huntington's disease (HD) in the development program for RG6042.

Detailed Study Description

Entry into the study should occur at the time the participant completes participation in one of the preceding studies. Upon completion of the inclusion visit, eligible patients will receive either RO7234292 (RG6042) every 8 weeks (Q8W) or RO7234292 (RG6042) every 16 weeks (Q16W) by bolus intrathecal injection.

Clinical Study Identifier: NCT03842969

Find a site near you

Start Over

Uab Medicine

Birmingham, AL United States
  Connect »

Stanford Univ Medical Center

Palo Alto, CA United States
  Connect »

SC3 Research Group, Inc

Pasadena, CA United States
  Connect »

Columbia University

New York, NY United States
  Connect »

University of Pittsburgh

Pittsburgh, PA United States
  Connect »

Northwestern University

Chicago, IL United States
  Connect »

Dent Neurological Institute

Amherst, NY United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.